Diagnosis of CLN2 disease may be reached through a mixture of clinical findings, TPP1 enzyme deficiency, and/or molecular findings in TPP1 (Fietz et al., 2016). This evidence concerns the gene TPP1 and hyperinsulinemic hypoglycemia, familial, 4.